canada glp 1 approves first generic GLP-1 drug in G7 This Week in GLP-1: A

Researchers warn that anyone taking Wegovy, Ozempic, Saxenda or Victoza may be at a higher risk of several digestive issues.

The Phase 3 ATTAIN-1 trial had good results that led to this approval, but not all positive: 12.4% average weight loss (27.3 lbs) at highest dose Lower than the 15-20% weight loss seen with injectables Wegovy and Zepbound Nearly 1/4 of participants on the highest dose reported vomiting Vomiting rates are much higher than injectable GLP-1s However, there is likely a niche for Foundayo (along with the pill version of Wegovy) due to convenience: No refrigeration requirements or injection site reactions Eliminates barriers for patients avoiding injectables due to stigma, needle aversion, or storage constraints It's possible we could see this as a "maintenance" therapy after an initial injectable course

to address the...

Front Endocrinol (Lausanne)

A clinically positioned GLP-1 metabolic support product provides a credible foundation for building a broader brand ecosystem that may include gut health, muscle preservation, collagen support, energy optimization, and longevity nutrition

a Google Sheets labeled tracker is included, though some Excel formatting may display slightly differently in Sheets